Galectin says NASH drug misses main goal of midstage trial

(Reuters) - Galectin Therapeutics Inc said on Tuesday its experimental drug for the complex progressive fatty liver disease NASH led to some clinically meaningful results in patients with cirrhosis, but failed to achieve the main goal of a midstage trial.